Perampanel 0.5 MG/ML Oral Suspension — RxCUI 1790122
RxNorm drug concept · Semantic clinical drug
RxCUI 1790122
Semantic clinical drug · SCD
● Current RxNorm concept 16 FDA products
32 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1790122
Official namePerampanel 0.5 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asperampanel 0.5 MG per 1 ML Oral Suspension; perampanel 0.5 MG in 1 mL Oral Suspension
FDA products mapped16
Package NDCs mapped32
Reported Medicaid activity (SDUD)63,501 prescriptions · 45 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Perampanel: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Perampanel is a seizure medicine used to treat two types of epilepsy: partial-onset seizures (seizures that start in one part of the brain) and primary generalized tonic-clonic sei...
- What is perampanel actually for — why did my doctor prescribe it?
- Taking perampanel at bedtime is intentional — it causes dizziness and drowsiness in many people, and sleeping through the worst of that makes it much easier to tolerate. It also he...
- Why do I have to take it at bedtime? Can I take it at a different time?
🕸️ Concept Web — How Perampanel 0.5 MG/ML Oral Suspension Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Perampanel 0.5 MG/ML Oral Suspension
RxCUI 1790122 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Perampanel
1356552IN
-
Perampanel
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
FYCOMPA
1356558BN
-
FYCOMPA
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Perampanel Oral Suspension
1790121SCDF -
Perampanel Oral Liquid Product
1790120SCDG -
Perampanel Oral Product
1356554SCDG -
Perampanel Oral Suspension [FYCOMPA]
1790124SBDF -
FYCOMPA Oral Liquid Product
1790125SBDG -
FYCOMPA Oral Product
1356561SBDG -
Oral Suspension
316969DF -
Oral Liquid Product
1151137DFG - +1 more in this family
-
Perampanel Oral Suspension
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Perampanel 0.5 MG/ML
1790119SCDC -
Perampanel 0.5 MG/ML Oral Suspension [FYCOMPA]
1790126SBD -
Perampanel 0.5 MG/ML [FYCOMPA]
1790123SBDC
-
Perampanel 0.5 MG/ML
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Perampanel 0.5 MG/ML
SCDC · 1790119 -
Perampanel Oral Suspension
SCDF · 1790121 -
Perampanel Oral Liquid Product
SCDG · 1790120 -
Perampanel Oral Product
SCDG · 1356554
Brand-Name Concepts
-
Perampanel 0.5 MG/ML Oral Suspension [FYCOMPA]
SBD · 1790126 -
Perampanel 0.5 MG/ML [FYCOMPA]
SBDC · 1790123 -
Perampanel Oral Suspension [FYCOMPA]
SBDF · 1790124 -
FYCOMPA Oral Liquid Product
SBDG · 1790125 -
FYCOMPA Oral Product
SBDG · 1356561 -
FYCOMPA
BN · 1356558
📦 FDA Products & Package NDCs
16 products · 32 package NDCs
32 package NDCs map to RxCUI 1790122 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 51672-4256-09 | 1 BOTTLE in 1 CARTON (51672-4256-9) / 340 mL in 1 BOTTLE | PERAMPANEL | Sun Pharmaceutical Industries, Inc. | 2026-06-16 |
| 62856-0272-14 | 14 TABLET in 1 PACKET (62856-272-14) | Fycompa | Eisai Inc. | 2018-08-08 |
| 62856-0272-30 | 30 TABLET in 1 BOTTLE (62856-272-30) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0272-90 | 90 TABLET in 1 BOTTLE (62856-272-90) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0274-14 | 14 TABLET in 1 PACKET (62856-274-14) | Fycompa | Eisai Inc. | 2018-08-08 |
| 62856-0274-30 | 30 TABLET in 1 BOTTLE (62856-274-30) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0274-90 | 90 TABLET in 1 BOTTLE (62856-274-90) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0276-30 | 30 TABLET in 1 BOTTLE (62856-276-30) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0276-90 | 90 TABLET in 1 BOTTLE (62856-276-90) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0278-30 | 30 TABLET in 1 BOTTLE (62856-278-30) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0278-90 | 90 TABLET in 1 BOTTLE (62856-278-90) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0280-30 | 30 TABLET in 1 BOTTLE (62856-280-30) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0280-90 | 90 TABLET in 1 BOTTLE (62856-280-90) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0282-30 | 30 TABLET in 1 BOTTLE (62856-282-30) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0282-90 | 90 TABLET in 1 BOTTLE (62856-282-90) | Fycompa | Eisai Inc. | 2012-10-22 |
| 62856-0290-38 | 340 mL in 1 BOTTLE (62856-290-38) | Fycompa | Eisai Inc. | 2016-04-30 |
| 69616-0272-14 | 14 TABLET in 1 PACKAGE (69616-272-14) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0272-30 | 30 TABLET in 1 BOTTLE (69616-272-30) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0272-90 | 90 TABLET in 1 BOTTLE (69616-272-90) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0274-14 | 14 TABLET in 1 PACKAGE (69616-274-14) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0274-30 | 30 TABLET in 1 BOTTLE (69616-274-30) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0274-90 | 90 TABLET in 1 BOTTLE (69616-274-90) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0276-30 | 30 TABLET in 1 BOTTLE (69616-276-30) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0276-90 | 90 TABLET in 1 BOTTLE (69616-276-90) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0278-30 | 30 TABLET in 1 BOTTLE (69616-278-30) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0278-90 | 90 TABLET in 1 BOTTLE (69616-278-90) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0280-30 | 30 TABLET in 1 BOTTLE (69616-280-30) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0280-90 | 90 TABLET in 1 BOTTLE (69616-280-90) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0282-30 | 30 TABLET in 1 BOTTLE (69616-282-30) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0282-90 | 90 TABLET in 1 BOTTLE (69616-282-90) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 69616-0290-38 | 340 mL in 1 BOTTLE (69616-290-38) | Fycompa | Catalyst Pharmaceuticals, Inc. | 2024-01-02 |
| 72205-0071-79 | 340 mL in 1 BOTTLE (72205-071-79) | PERAMPANEL | Novadoz Pharmaceuticals LLC | 2025-12-15 |
Observed labelers:
Catalyst Pharmaceuticals, Inc. (15) ·
Eisai Inc. (15) ·
Novadoz Pharmaceuticals LLC (1) ·
Sun Pharmaceutical Industries, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.